The short bowel syndrome therapy developer has added $110m to the $35m with which it emerged from stealth in January.
Switzerland-headquartered rare disease drug developer VectivBio has completed $110m in crossover financing from investors including pharmaceutical firm Novo.
The round also featured Inserm Transfer Initiative, a vehicle for public research organisation firm Inserm, as well as Surveyor Capital, Cormorant Capital, Eventide Asset Management, Versant Ventures, OrbiMed, BPIfrance, Tekla Healthcare Investors and Cowen Healthcare Investments.
VectivBio is developing a therapy called apraglutide to treat a condition known as short bowel syndrome (SBS) which is caused by the lack of a functional…
